

Status: Currently Official on 16-Feb-2025

Official Date: Official as of 01-Dec-2016

Document Type: USP Monographs

DocId: GUID-F7B146DE-4808-42A3-AB3A-9F9213BCC0FF\_1\_en-US

DOI: [https://doi.org/10.31003/USPNF\\_M1721\\_01\\_01](https://doi.org/10.31003/USPNF_M1721_01_01)

DOI Ref: p3p0y

© 2025 USPC

Do not distribute

## Piroxicam Compounded Cream

### DEFINITION

Piroxicam Compounded Cream contains NLT 90.0% and NMT 110.0% of the labeled amount of piroxicam ( $C_{15}H_{13}N_3O_4S$ ).

Prepare Piroxicam Compounded Cream as follows (see [Pharmaceutical Compounding—Nonsterile Preparations \(795\)](#)).

Piroxicam	3 g
White Petrolatum	25 g
Stearyl Alcohol	15 g
Propylparaben	0.06 g
Methylparaben	0.15 g
Propylene Glycol	12.0 g
Sodium Lauryl Sulfate	1 g
Sodium Hydroxide, 1 N	2.5 mL
Purified Water, a sufficient quantity to make	100 g

In an appropriate container (final weight tared), mix the *White Petrolatum* and *Stearyl Alcohol* together, and heat to  $80 \pm 5^\circ$  to form a clear oil phase. In a separate container, mix the *Propylparaben*, *Methylparaben*, *Propylene Glycol*, *Sodium Lauryl Sulfate*, and about 30 mL of *Purified Water* together, and heat to  $80 \pm 5^\circ$  to form a clear aqueous phase. Add the aqueous phase to the oil phase with continuous stirring, and allow it to cool to  $50^\circ$  to form an emulsion. In a mortar, triturate the *Piroxicam* with the *Sodium Hydroxide* to form a suspension. Using additional *Purified Water* to rinse the mortar, add the piroxicam suspension to the previously prepared emulsion, transferring the suspension stepwise and quantitatively to the emulsion. Add sufficient *Purified Water* with stirring to bring to final weight. Package, and label.

### ASSAY

#### • PROCEDURE

**Solution A:** 2.7 g/L of citric acid and 5.4 g/L of dibasic sodium phosphate in *Purified Water*. Pass through a filter of 0.45- $\mu$ m pore size.

**Mobile phase:** Methanol and *Solution A* (50:50). Filter, and degas.

**Diluent:** 0.01 N methanolic hydrochloric acid prepared by diluting 0.9 mL of hydrochloric acid with methanol to a final volume of 1 L

**Standard solution:** Dissolve an accurately weighed quantity of [USP Piroxicam RS](#) in 2 mL of chloroform, and dilute with *Diluent* to obtain a solution with a nominal concentration of about 50  $\mu$ g/mL of piroxicam.

**Sample solution:** Add 340 mg of Cream to 4 mL of chloroform and 150 mL of *Diluent*. Shake the mixture on a wrist action shaker for 15 min, and dilute with *Diluent* to 200 mL. Pass the solution through a filter of 0.45- $\mu$ m pore size, and discard the first 5 mL of the filtrate.

**Blank:** Add 340 mg of *Purified Water* to 4 mL of chloroform and 150 mL of *Diluent*. Shake the mixture on a wrist action shaker for 15 min, and dilute with *Diluent* to 200 mL. Pass the solution through a filter of 0.45- $\mu$ m pore size, and discard the first 5 mL of the filtrate.

#### Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

**Mode:** LC

**Detector:** UV 254 nm

**Columns**

**Guard:** 4.6-mm  $\times$  2-cm; packing L1

**Analytical:** 4.6-mm × 30-cm; 10-µm packing L1**Flow rate:** 1.0 mL/min**Injection volume:** 20 µL**System suitability****Sample:** Standard solution

[NOTE—The retention time for piroxicam is about 7 min.]

**Suitability requirements****Relative standard deviation:** NMT 2.8% for replicate injections**Analysis****Samples:** Standard solution, Sample solution, and BlankCalculate the percentage of the labeled amount of piroxicam ( $C_{15}H_{13}N_3O_4S$ ) in the portion of Cream taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

 $r_U$  = peak response from the Sample solution $r_S$  = peak response from the Standard solution $C_S$  = concentration of [USP Piroxicam RS](#) in the Standard solution (µg/mL) $C_U$  = nominal concentration of piroxicam in the Sample solution (µg/mL)**Acceptance criteria:** 90.0%–110.0%**ADDITIONAL REQUIREMENTS**

- PACKAGING AND STORAGE:** Package in a tight, light-resistant, plastic resealable container. Store at controlled room temperature.
- Beyond-Use Date:** NMT 90 days after the date on which it was compounded when stored at controlled room temperature
- LABELING:** Label it to state the Beyond-Use Date.
- USP REFERENCE STANDARDS (11).**

[USP Piroxicam RS](#)Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
PIROXICAM COMPOUNDED CREAM	<a href="#">Brian Serumaga</a> Science Program Manager	CMP2020 Compounding 2020
REFERENCE STANDARD SUPPORT	RS Technical Services <a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a>	CMP2020 Compounding 2020

**Chromatographic Database Information:** [Chromatographic Database](#)**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. PF 40(6)

**Current DocID: GUID-F7B146DE-4808-42A3-AB3A-9F9213BCC0FF\_1\_en-US****DOI:** [https://doi.org/10.31003/USPNF\\_M1721\\_01\\_01](https://doi.org/10.31003/USPNF_M1721_01_01)**DOI ref:** [p3p0y](#)